Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

MDMA Toxicity Treatment & Management

  • Author: In-Hei Hahn, MD, FACEP; Chief Editor: Asim Tarabar, MD  more...
 
Updated: Jul 07, 2016
 

Prehospital Care

Prehospital care is primarily supportive.

Address the ABCs, administer oxygen, obtain intravenous access, assess blood glucose level, monitor the patient, and perform frequent vital sign checks and serial assessment of consciousness (eg, AVPU [alert, responds to voice, responds to pain, unresponsive], Glasgow Coma Scale).

Anxiety, extreme agitation, panic reactions, and seizures may require short-acting benzodiazepines (eg, lorazepam) administered intravenously or intramuscularly. Restraints may be necessary if patients exhibit complete loss of control and are dangerous to themselves or others.

Next

Emergency Department Care

While most patients with MDMA overdose improve with supportive care, life-threatening complications may result from severe toxicity. Fatalities have been reported because of severe hyperthermia (ie, heat stroke) accompanied by disseminated intravascular coagulation, rhabdomyolysis, and acute renal failure. Death from cerebral edema and seizures secondary to hyponatremia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) has also been reported. As in any amphetamine toxicity, the danger of cardiac arrhythmias and cardiovascular instability always must be entertained.

Careful attention to the airway, breathing, and circulation (ABCs) and vital signs is standard in overdoses, and serial neurologic checks are required. Provide oxygen, obtain intravenous access, and perform cardiac monitoring.

A bedside glucose determination is indicated in any patient presenting with altered mental status. If a patient is hypoglycemic, administer thiamine and enough glucose to maintain adequate serum glucose concentrations with frequent monitoring.

If verbal communication is possible, providing reassurance is important. Avoid physical or pharmacologic restraints if possible. Place the patient in a calm, quiet room. If severe agitation or disruptive behavior persists, sedation using benzodiazepines and/or physical restraints may be necessary.

If acute toxicity caused by ingestion is known, perform gastrointestinal decontamination by administering activated charcoal. Orogastric lavage usually is not necessary unless a life-threatening co-ingestant is involved and the patient presents within 1 hour of ingestion. Whole-bowel irrigation may be indicated if body packing of drugs is suspected.

Although respiratory distress is uncommon, endotracheal intubation and mechanical ventilation may be required in patients who cannot protect their airway or have respiratory compromise because of conditions such as seizures, cardiovascular instability, or trauma.

Patients presenting with severe hyperthermia require aggressive cooling measures and adequate fluid resuscitation. Obtain a rectal temperature. Aggressively cool hyperthermic patients to 102°F. Morbidity is directly related to the severity and duration of hyperthermia. Management considerations are as follows:

  • Undress the patient
  • Apply evaporative cooling with water and a fan
  • Apply ice packs to the groin and axilla
  • Iced gastric lavage may be considered
  • In extreme cases, ice-bath immersion may be required for the correction of hyperthermia
  • Control shivering with a benzodiazepine
  • Antipyretics are not useful

Dantrolene (1 mg/kg or 80 mg intravenously [IV]) has been used for the treatment of hyperpyrexia after conventional therapy. Dantrolene is typically used to treat malignant hyperthermia, a genetic disorder of the skeletal muscle due to a defect in the ryanodine receptor that allows for massive release of calcium from the sarcoplasmic reticulum during exposures to general anesthetics.

MDMA-induced hyperthermia is thought to be centrally medicated from via serotonin toxicity. Although the mechanism of dantrolene does not seem to correlate with what is known about MDMA-induced hyperthermia, dantrolene was first used to treat hyperthermia in the setting of MDMA-related hyperpyrexia in 1992 due to the similarity of presentation.

A systematic compilation of MDMA case reports suggests that there may be some evidence of benefit in using dantrolene to treat hyperthermia.[24] The study showed decreased morbidity and mortality with rare side effects from the dantrolene itself, especially in patients who present with temperatures above 40°C, especially above 42°C. The biggest caveat with using case series and case reports is recognizing the limitations of reporting and publication biases.

A study in an animal model found that clozapine resulted in a marked and immediate reversal of MDMA-induced hyperthermia, via inhibition of brain metabolic activation and blockade of skin vasoconstriction. Carvedilol was modestly effective in attenuating MDMA-induced hyperthermia, and labetalol was ineffective.[25]

Treat seizures with benzodiazepines. Most seizures are self-limited and respond well to benzodiazepines. Protect the airway and consider phenobarbital or propofol in patients with refractory symptoms. Treat the underlying cause and check electrolytes, especially hyponatremia. Start with fluid restriction, but consider adding hypertonic saline in refractory or severe cases; in these cases, adding 3% saline and furosemide may be indicated but at a rate no greater than 0.5-1 mEq/L/h.

Foley catheter placement is indicated to monitor urine output in patients with rhabdomyolysis. Check urinalysis for myoglobin and creatine kinase for rhabdomyolysis. Recognition and treatment of rhabdomyolysis with fluids, alkalinization of the urine, and furosemide may be indicated to prevent acute renal failure. Alkalinization of the urine with sodium bicarbonate is helpful. Administration of furosemide and mannitol may also be considered.

Obtain cardiac monitoring and an electrocardiogram in patients complaining of chest pain or palpitations. Order appropriate cardiac enzyme measurements if cardiac injury is suggested. Significant cardiac dysrhythmias may require pharmacotherapy or cardioversion and/or defibrillation.

Initially, manage hypertension with benzodiazepine sedation. In patients with refractory symptoms or signs of end-organ damage, nitroprusside or nitroglycerin can be used to lower the blood pressure.

Always perform pregnancy testing in female patients with overdose. MDMA, like all amphetamines, can be toxic to the fetus and may induce miscarriage or premature labor.

Previous
Next

Consultations

See the list below:

  • A regional poison control center and medical toxicologist can provide valuable information and instructions for handling complex ingestions. Bedside consultation or admission (if necessary) by a medical toxicologist may be beneficial in these situations.
  • Obtain psychiatric consultation for patients who demonstrate suicidal thoughts or behavior.
Previous
 
 
Contributor Information and Disclosures
Author

In-Hei Hahn, MD, FACEP Attending Physician, Department of Emergency Medicine, NYU Langone-Cobble Hill; Senior Associate Attending Physician, Department of Emergency Medicine, Mount Sinai St Luke's-Roosevelt Hospital

In-Hei Hahn, MD, FACEP is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John G Benitez, MD, MPH Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center

John G Benitez, MD, MPH is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Undersea and Hyperbaric Medical Society, Wilderness Medical Society, American College of Occupational and Environmental Medicine

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Peter MC DeBlieux, MD Professor of Clinical Medicine and Pediatrics, Section of Pulmonary and Critical Care Medicine, Program Director, Department of Emergency Medicine, Louisiana State University School of Medicine in New Orleans

Peter MC DeBlieux, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Radiological Society of North America, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author David Yew, MD, to the original writing and development of this article.

References
  1. McCann UD, Eligulashvili V, Ricaurte GA. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology. 2000. 42(1):11-6. [Medline].

  2. Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther. 1992 May. 261(2):616-22. [Medline].

  3. Steele TD, McCann UD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction. 1994 May. 89(5):539-51. [Medline].

  4. Schwartz RH, Miller NS. MDMA (ecstasy) and the rave: a review. Pediatrics. 1997 Oct. 100(4):705-8. [Medline].

  5. Aitchison KJ, Tsapakis EM, Huezo-Diaz P, Kerwin RW, Forsling ML, Wolff K. Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. J Psychopharmacol. 2012 Mar. 26(3):408-18. [Medline].

  6. Nadkarni GN, Hoskote SS, Piotrkowski J, Annapureddy N. Serotonin Syndrome, Disseminated Intravascular Coagulation, and Hepatitis After a Single Ingestion of MDMA in an Asian Woman. Am J Ther. 2012 Jun 16. [Medline].

  7. Cunningham M. Ecstasy-induced rhabdomyolysis and its role in the development of acute renal failure. Intensive Crit Care Nurs. 1997 Aug. 13(4):216-23. [Medline].

  8. Fahal IH, Sallomi DF, Yaqoob M, Bell GM. Acute renal failure after ecstasy. BMJ. 1992 Jul 4. 305(6844):29. [Medline].

  9. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA ("ecstasy") induces vasopressin secretion. Lancet. 1998 Jun 13. 351(9118):1784. [Medline].

  10. Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA). Lancet. 1996 Apr 13. 347(9007):1052. [Medline].

  11. Carvalho M, Pontes H, Remiao F, Bastos ML, Carvalho F. Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol. 2010 Aug. 11(5):476-95. [Medline].

  12. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B. Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berl). 2000 Feb. 148(3):322-4. [Medline].

  13. National Institute on Drug Abuse. National Survey of Drug Use and Health. Available at https://www.drugabuse.gov/national-survey-drug-use-health. Accessed: July 6, 2016.

  14. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Substance Abuse and Mental Health Services Administration. 2013. Available at http://www.samhsa.gov/data/2k13/DAWN2k11ED/DAWN2k11ED.htm.

  15. Drug Abuse Warning Network (DAWN) Reports 2005. [Electronic Version]. Retrieved June 8, 2008 from http://dawninfo.samhsa.gov/.

  16. Palamar JJ, Keyes K, Cleland CM. Underreporting of ecstasy use among high school seniors in the US. Drug Alcohol Depend. 2016 Jun 6. [Medline].

  17. Wish ED, Fitzelle DB, O'Grady KE, Hsu MH, Arria AM. Evidence for significant polydrug use among ecstasy-using college students. J Am Coll Health. 2006 Sep-Oct. 55(2):99-104. [Medline]. [Full Text].

  18. European Monitoring Centre for Drugs and Drug Addiction. Methylenedioxymethamphetamine (MDMA or 'Ecstasy'). EMCDDA. Available at http://www.emcdda.europa.eu/publications/drug-profiles/mdma. Accessed: October 6, 2014.

  19. United Nations Office on Drugs and Crime. World Drug Report 2014. UNODC. Available at http://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf. Accessed: October 6. 2014.

  20. O'Shea E, Escobedo I, Orio L, et al. Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology. 2005 Jul. 30(7):1312-23. [Medline].

  21. Lai TI, Hwang JJ, Fang CC, Chen WJ. Methylene 3, 4 dioxymethamphetamine-induced acute myocardial infarction. Ann Emerg Med. 2003 Dec. 42(6):759-62. [Medline].

  22. Monitoring the Future Study: Trends in Prevalence of Various Drugs. National Institute on Drug Abuse. Available at https://www.drugabuse.gov/trends-statistics/monitoring-future/monitoring-future-study-trends-in-prevalence-various-drugs. Accessed: July 6, 2016.

  23. Papaseit E, Pérez-Mañá C, Mateus JA, Pujadas M, Fonseca F, Torrens M, et al. Human Pharmacology of Mephedrone in Comparison to MDMA. Neuropsychopharmacology. 2016 May 20. [Medline].

  24. Grunau BE, Wiens MO, Brubacher JR. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM. 2010 Sep. 12(5):435-42. [Medline].

  25. Kiyatkin EA, Ren S, Wakabayashi KT, Baumann MH, Shaham Y. Clinically Relevant Pharmacological Strategies That Reverse MDMA-Induced Brain Hyperthermia Potentiated by Social Interaction. Neuropsychopharmacology. 2016 Jan. 41 (2):549-59. [Medline].

  26. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH. Congenital anomalies after prenatal ecstasy exposure. Lancet. 1999 Oct 23. 354(9188):1441-2. [Medline].

  27. Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol. 1998 Sep. 29(3):394-7. [Medline].

  28. Burgess C, O'Donohoe A, Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry. 2000 Aug. 15(5):287-94. [Medline].

  29. Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep. 101(9):1241-5. [Medline].

  30. Galineau L, Belzung C, Kodas E, Bodard S, Guilloteau D, Chalon S. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) exposure induces long-term alterations in the dopaminergic and serotonergic functions in the rat. Brain Res Dev Brain Res. 2005 Feb 8. 154(2):165-76. [Medline].

  31. Joseph M. Ecstasy - Its History and Lore. Carlton Books; 2000. 1-96.

  32. Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking "ecstasy". BMJ. 1993 Nov 27. 307(6916):1399. [Medline].

  33. Saadat KS, O'shea E, Colado MI, Elliott JM, Green AR. The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ('ecstasy') when housed at high ambient temperature. Psychopharmacology (Berl). 2005 Jun. 179(4):884-90. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.